We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Wins RSV Vaccine Race, But Pfizer May Be Close Behind
GSK Wins RSV Vaccine Race, But Pfizer May Be Close Behind
GSK has crossed the finish line with Arexvy (RSVPreF3-AS01E), the first respiratory syncytial virus (RSV) vaccine to win FDA approval for individuals age 60 years and older, but approval of Pfizer’s RSV candidate, Abrysvo (RSVpreF), may not be far behind.